Aquestive Therapeutics (AQST) Share-based Compensation (2018 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Share-based Compensation of $2.3 million for Q1 2026, up 229.73% year-over-year from $703000.0 in Q1 2025, and down 66.07% quarter-over-quarter from $6.8 million in Q4 2025.
Aquestive Therapeutics (AQST) Share-based Compensation (2018 - 2026) Analysis & Trends
Aquestive Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 229.73% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $9.2 million (up 914.16% YoY), while the FY2025 annual figure was $7.6 million, up 592.46% from the prior year.
- Share-based Compensation for Q1 2026 stood at $2.3 million, down from $6.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $6.8 million in Q4 2025, with the low at -$3.6 million in Q4 2024.
- The 5-year median for Share-based Compensation is $833500.0 (2023), against an average of $981071.4.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 482.45% in 2024, then jumped 55260.0% in 2025.
- Aquestive Therapeutics' Share-based Compensation stood at $3000.0 in 2022, then soared by 31233.33% to $940000.0 in 2023, then sank by 482.45% to -$3.6 million in 2024, then soared by 290.04% to $6.8 million in 2025, then tumbled by 66.07% to $2.3 million in 2026.
- Business Quant data shows AQST's Share-based Compensation at $2.3 million in Q1 2026, $6.8 million in Q4 2025, and -$2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.90 Mn |
| Jun 30, 2026 | 2.90 Mn |
| Mar 31, 2026 | 2.32 Mn |
| Mar 31, 2026 | 2.32 Mn |
| Dec 31, 2025 | 6.83 Mn |
| Dec 31, 2025 | 6.83 Mn |
| Sep 30, 2025 | -2.68 Mn |
| Sep 30, 2025 | -2.68 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Mar 31, 2025 | 703,000.00 |
| Mar 31, 2025 | 703,000.00 |
| Dec 31, 2024 | -3.60 Mn |
| Dec 31, 2024 | -3.60 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 893,000.00 |
| Mar 31, 2024 | 893,000.00 |